

Kurt R Brunden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7052469/publications.pdf>

Version: 2024-02-01

51
papers

3,947
citations

159358

30
h-index

205818

48
g-index

51
all docs

51
docs citations

51
times ranked

5261
citing authors

#	ARTICLE	IF	CITATIONS
1	Amyloid- β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. <i>Nature Medicine</i> , 2018, 24, 29-38.	15.2	433
2	Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 783-793.	21.5	383
3	The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice. <i>Journal of Neuroscience</i> , 2012, 32, 3601-3611.	1.7	325
4	Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy. <i>Journal of Neuroscience</i> , 2010, 30, 13861-13866.	1.7	256
5	Chronic Stress Exacerbates Tau Pathology, Neurodegeneration, and Cognitive Performance through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic Mouse Model of Tauopathy. <i>Journal of Neuroscience</i> , 2011, 31, 14436-14449.	1.7	201
6	Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. <i>Neurobiology of Disease</i> , 2015, 73, 83-95.	2.1	168
7	Microtubule Stabilizing Agents as Potential Treatment for Alzheimer's Disease and Related Neurodegenerative Tauopathies. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8979-8996.	2.9	151
8	The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. <i>Pharmacological Research</i> , 2011, 63, 341-351.	3.1	135
9	Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation. <i>Journal of Biological Chemistry</i> , 2013, 288, 11024-11037.	1.6	128
10	Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models. <i>PLoS ONE</i> , 2015, 10, e0125614.	1.1	124
11	Evidence that Non-Fibrillar Tau Causes Pathology Linked to Neurodegeneration and Behavioral Impairments. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 393-399.	1.2	106
12	Identification of Aminothienopyridazine Inhibitors of Tau Assembly by Quantitative High-Throughput Screening. <i>Biochemistry</i> , 2009, 48, 7732-7745.	1.2	101
13	Developing Therapeutic Approaches to Tau, Selected Kinases, and Related Neuronal Protein Targets. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a006437-a006437.	2.9	101
14	Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. <i>Alzheimer's and Dementia</i> , 2016, 12, 1051-1065.	0.4	91
15	Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5040-5049.	1.4	87
16	Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer's Disease and Related Tauopathies. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6116-6127.	2.9	84
17	Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors. <i>Experimental Neurology</i> , 2010, 223, 304-310.	2.0	81
18	Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. <i>Neurobiology of Disease</i> , 2017, 105, 328-335.	2.1	74

#	ARTICLE	IF	CITATIONS
19	1,2,4-Triazolo[1,5-a]pyrimidines in drug design. <i>European Journal of Medicinal Chemistry</i> , 2019, 165, 332-346.	2.6	68
20	The Dynamics and Turnover of Tau Aggregates in Cultured Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 13175-13193.	1.6	59
21	Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimers Disease and Related Tauopathies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 357, 432-450.	1.3	58
22	Identification of Novel and Improved Antimitotic Agents Derived from Noscapine. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7096-7098.	2.9	56
23	Discovery of Brain-Penetrant, Orally Bioavailable Aminothienopyridazine Inhibitors of Tau Aggregation. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3739-3747.	2.9	47
24	Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 106.	2.4	45
25	Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5120-5145.	2.9	40
26	Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. <i>Biochemical Society Transactions</i> , 2012, 40, 661-666.	1.6	39
27	Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors. <i>Scientific Reports</i> , 2016, 5, 18286.	1.6	37
28	Characterization of tau binding by gosuranemab. <i>Neurobiology of Disease</i> , 2020, 146, 105120.	2.1	36
29	MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 886-889.	1.3	33
30	Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 864-868.	1.3	32
31	Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4980-4982.	1.0	31
32	Characterization of novel conformation-selective β -synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 136, 104712.	2.1	31
33	In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics. <i>Acta Neuropathologica</i> , 2021, 141, 193-215.	3.9	30
34	Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 4451-4461.	1.4	29
35	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. <i>Acta Neuropathologica</i> , 2022, 143, 15-31.	3.9	29
36	A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model. <i>Molecular Neurodegeneration</i> , 2018, 13, 59.	4.4	27

#	ARTICLE	IF	CITATIONS
37	Brain-Penetrant Tetrahydronaphthalene Thromboxane A ₂ -Prostanoid (TP) Receptor Antagonists as Prototype Therapeutics for Alzheimer's Disease. ACS Chemical Neuroscience, 2012, 3, 928-940.	1.7	22
38	Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2180-2183.	1.0	21
39	Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies. ACS Chemical Neuroscience, 2017, 8, 5-7.	1.7	20
40	Brain-Penetrant Triazolopyrimidine and Phenylpyrimidine Microtubule Stabilizers as Potential Leads to Treat Human African Trypanosomiasis. ChemMedChem, 2018, 13, 1751-1754.	1.6	19
41	Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer's disease. Molecular Neurodegeneration, 2020, 15, 64.	4.4	19
42	Effects of microglial depletion and TREM2 deficiency on A β plaque burden and neuritic plaque tau pathology in 5XFAD mice. Acta Neuropathologica Communications, 2021, 9, 150.	2.4	19
43	Evaluation of the Structure-Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-a]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies. Journal of Medicinal Chemistry, 2021, 64, 1073-1102.	2.9	17
44	A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research. , 2012, 8, 564-573.		16
45	Correction of microtubule defects within A β plaque-associated dystrophic axons results in lowered A β release and plaque deposition. Alzheimer's and Dementia, 2020, 16, 1345-1357.	0.4	11
46	Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays. Journal of Biological Chemistry, 2020, 295, 4001-4013.	1.6	10
47	Potent, Long-Acting Cyclopentane-1,3-Dione Thromboxane (A ₂)-Receptor Antagonists. ACS Medicinal Chemistry Letters, 2014, 5, 1015-1020.	1.3	6
48	Congeners Derived from Microtubule-Active Phenylpyrimidines Produce a Potent and Long-Lasting Paralysis of <i>Schistosoma mansoni</i> In Vitro. ACS Infectious Diseases, 2021, 7, 1089-1103.	1.8	6
49	Microtubule-Stabilizing Agents for Alzheimer's and Other Tauopathies. Topics in Medicinal Chemistry, 2016, , 159-179.	0.4	5
50	O3-12-05: INTRACEREBRAL INJECTION OF PREFORMED SYNTHETIC TAU FIBRILS INITIATES WIDESPREAD TAUOPATHY AND NEURONAL LOSS IN THE BRAINS OF TAU TRANSGENIC MICE. , 2014, 10, P234-P234.		0
51	Alzheimer's Disease Drug Discovery in Academia: From High-Throughput Screening to In Vivo Testing. , 2022, , 34-44.		0